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Abstract: OBJECTIVES Predictors of chronic kidney disease (CKD) amongst HIV-positive persons are
well established, but insights into the prognosis after CKD including the role of modifiable risk factors are
limited. DESIGN Prospective cohort study. METHODS D:A:D participants developing CKD (confirmed,
>3 months apart, eGFR ฀ 60 ml/min per 1.73 m or 25% eGFR decrease when eGFR ฀ 60 ml/min
per 1.73 m) were followed to incident serious clinical events (SCE); end stage renal and liver disease
(ESRL and ESLD), cardiovascular disease (CVD), AIDS-defining and non-AIDS-defining malignancies
(NADM), other AIDS or death, 6 months after last visit or 1 February 2016. Poisson regression models
considered associations between SCE and modifiable risk factors. RESULTS During 2.7 (IQR 1.1-5.1)
years median follow-up 595 persons with CKD (24.1%) developed a SCE [incidence rate 68.9/1000 PYFU
(95% confidence interval 63.4-74.4)] with 8.3% (6.9-9.0) estimated to experience any SCE at 1 year. The
most common SCE was death (12.7%), followed by NADM (5.8%), CVD (5.6%), other AIDS (5.0%) and
ESRD (2.9%). Crude SCE ratios were significantly higher in those with vs. without CKD, strongest for
ESRD [65.9 (43.8-100.9)] and death [4.8 (4.3-5.3)]. Smoking was consistently associated with all CKD-
related SCE. Diabetes predicted CVD, NADM and death, whereas dyslipidaemia was only significantly
associated with CVD. Poor HIV-status predicted other AIDS and death, eGFR less than 30 ml/min per
1.73 m predicted CVD and death and low BMI predicted other AIDS and death. CONCLUSION In an
era where many HIV-positive persons require less monitoring because of efficient antiretroviral treatment,
persons with CKD carry a high burden of SCE. Several potentially modifiable risk factors play a central
role for CKD-related morbidity and mortality.
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Objectives: Predictors of chronic kidney disease (CKD) amongst HIV-positive persons
are well established, but insights into the prognosis after CKD including the role of
modifiable risk factors are limited.
Design: Prospective cohort study.
Methods: D:A:DparticipantsdevelopingCKD(confirmed,>3monthsapart, eGFR60ml/
minper1.73m2or25%eGFRdecreasewheneGFR60ml/minper1.73m2)were followed
to incident serious clinical events (SCE); end stage renal and liver disease (ESRL and ESLD),
cardiovasculardisease (CVD),AIDS-definingandnon-AIDS-definingmalignancies (NADM),
other AIDS or death, 6 months after last visit or 1 February 2016. Poisson regression models
considered associations between SCE and modifiable risk factors.
Results: During 2.7 (IQR 1.1–5.1) years median follow-up 595 persons with CKD
(24.1%) developed a SCE [incidence rate 68.9/1000 PYFU (95% confidence interval
63.4–74.4)] with 8.3% (6.9–9.0) estimated to experience any SCE at 1 year. The most
common SCE was death (12.7%), followed by NADM (5.8%), CVD (5.6%), other AIDS
(5.0%) and ESRD (2.9%). Crude SCE ratios were significantly higher in those with vs.
without CKD, strongest for ESRD [65.9 (43.8–100.9)] and death [4.8 (4.3–5.3)].
Smoking was consistently associated with all CKD-related SCE. Diabetes predicted
CVD, NADM and death, whereas dyslipidaemia was only significantly associated with
CVD. Poor HIV-status predicted other AIDS and death, eGFR less than 30ml/min per
1.73m2 predicted CVD and death and low BMI predicted other AIDS and death.
Conclusion: In an era where many HIV-positive persons require less monitoring
because of efficient antiretroviral treatment, persons with CKD carry a high burden
of SCE. Several potentially modifiable risk factors play a central role for CKD-related
morbidity and mortality. Copyright  2019 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
As chronic kidney disease (CKD) has become increas-
ingly common in the ageing community of people living
with HIV (PLWH), considerable efforts have gone into
uncovering potential predictors [1–4]. As such it is now
commonly accepted that HIV-related factors (such as
immunosuppression), co-infections, traditional renal risk
factors (such as diabetes and hypertension) and drug
toxicities play a central role for incident CKD in PLWH
[5–10].
Meanwhile, our insights into the more general morbidity
burden after acquiring CKD in PLWH and the associated
modifiable risk factors are still relatively limited [8,11–
15]. In a prior D:A:D analysis, we showed that up to 23%
of PLWH have the potential to improve kidney function
after moderate CKD (stages G3þ), whereas 65%
stabilized at their current estimated glomerular filtration
rate (eGFR) level and 12% continued to progress over the
next 36 months [16,17]. However, that analysis focused
exclusively on eGFR-defined outcomes. Large popula-
tion studies in the general HIV-negative population
suggest that individuals with advanced and end-stage
CKD (stages G4þ) have a particularly poor prognosis
with high morbidity and mortality [18,19]. Studies on
outcomes after CKD stage G3þ are somewhat scarcer,
likely because more moderate levels of CKD remain
undiagnosed and are associated with lower rates of
adverse outcomes than more advanced CKD stages. Large
studies with long follow-up times are, therefore, required
to reliably study the natural history of disease progression
in this group [15,19–21].
Related to the significantly improved health of PLWH, the
majority of stable PLWH on antiretroviral treatment
(ART) are only seen in clinical care once or twice annually.
The increasingCKD incidence in PLWH, however,makes
it imperative to better understand the consequences of
CKD in order to assist clinical identification of those at
highest risk of severe morbidity and mortality. Identifica-
tion of key factors driving CKD-related morbidity will
further improve our understanding of the disease
mechanistic and where to focus interventions [22].
Using the large D:A:D (Data collection on Adverse events
of Anti-HIV Drugs) cohort the aim of this analysis is to
investigate the disease spectrum and the prognosis after a
diagnosis of CKD stage G3þ in PLWHwith focus on the




The D:A:D study is a large observational cohort
collaboration initiated in 1999 based on a request from
the European Medicines Agency (EMA) to study adverse
drug effects of ART and comorbidities in PLWH, details
have been published previously [23]. From the 11
contributing cohorts in Europe, the United States and
Australia, more than 49 000 HIV-1-positive persons were
under prospective follow-up. Data on clinical events were
reported on designated event forms and include
cardiovascular disease (CVD), end-stage renal and liver
disease (ESRD and ESLD), cancers and fatal cases (for
details see https://www.chip.dk/Studies/DAD/Study-
Documents). Events were collected in real-time during
routine clinical care, centrally validated against predefined
algorithms, regularly monitored and reviewed by external
experts. In addition, electronic data were collected at
enrolment and at every 6 months thereafter on
demographics, detailed records of ART and other key
HIV-variables including HIV viral load (VL), CD4þ cell
counts, AIDS events and viral hepatitis. In addition,
CVD-related risk factors (such as familiar disposition,
hypertension, diabetes, dyslipidemia and smoking) and
treatment (such as antihypertensives and antiplatelets)
were captured. Finally, data on selected common
laboratory biomarkers (such as haemoglobin, renal and
liver function markers) was systematically collected.
Endpoint definitions and statistical analyses
The SCE included were centrally validated CVD
[myocardial infarction (MI), stroke, invasive cardiovascu-
lar procedures], ESRD, ESLD, AIDS-defining malignan-
cies (ADM), non-AIDS defining malignancies (NADM),
other AIDS events (excluding malignancies) and death
from any cause.
Creatinine was collected systematically in D:A:D from
2004. We calculated creatinine clearance, used as an
eGFR surrogate, as in earlier D:A:D analyses, using the
Cockcroft–Gault equation [24], standardized for body
surface area [25,26]. As several specific cohorts in D:A:D
are prohibited from collecting ethnicity information the
Cockcroft–Gault equation was used rather than an
equation including ethnicity.
CKD was defined as confirmed,>3 months apart, eGFR
60ml/min per 1.73m2 or a 25% decrease in eGFR level
when baseline eGFR 60ml/min per 1.73m2 or less
[7,27]. For our main analysis of SCE after CKD,
participants were followed from time of CKD diagnosis
to incident SCE, 6 months after last visit or 1 February
2016, whichever occurred first. Although participants
could experience several different types of incident SCE
after CKD, recurrences of the same specific subtype of
SCE were excluded from this analysis (e.g. someone with
a prior MI could not progress to another MI but could
progress to a different CVD event, such as a stroke). A
separate analysis was performed for each of the SCE.
For perspectives, in a purely descriptive analysis, we
followed participants fromfirst eGFR to SCE and stratified
2174 AIDS 2019, Vol 33 No 14
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follow-up time according to CKD status and compared
crude rates of SCE between those with/without CKD. As
the baseline, study population and follow-up are defined
differently in this subanalysis, SCE rates will not be directly
comparable with those of the primary analysis.
Adjusted Poisson regression models considered associa-
tions between individual SCE and potentialmodifiable risk
factors. Factors included in multivariable analysis were
decided a priori based on the factors associated with CKD
and each of the SCE in previous D:A:D analyses [7,11,23].
These included demographics (sex, age, ethnic origin,
cohort), HIV-related factors (HIVacquisition risk, CD4þ
cell count, prior AIDS and viral hepatitis co-infection) and
more traditional risk factors (familial disposition to CVD,
hypertension, dyslipidaemia, BMI and eGFR30ml/min
per 1.73m2).We further defined poorHIV-status as CD4þ
cell count less than 350 cells/ml or VL greater than
10000 copies/ml, good HIV-status as CD4þ cell count
greater than 500 cells/ml and VL less than 400 copies/ml;
and intermediate status as all other combinations. We also
included adjustment for any prior and time-updated
specific SCE.We did not includeART in our models aswe
have previously shown that specific antiretrovirals, which
are known to be nephrotoxic, are often actively switched
once an individual’s eGFR starts to decline but before they
reach the threshold for CKD, meaning post-CKD analyses
will be highly confounded by indication for ART and
difficult to interpret [6,16]. Potential risk factorswere fitted
as time-updated variables when subjected to change over
time (e.g. age) otherwise as time-fixed (baseline) values
(e.g. ethnic origin). Interactions were considered between
poor HIV-status, smoking, diabetes and low BMI. To
address, which potentially modifiable risk factors have the
strongest impact on the prognosis after CKD,we calculated
the population attributable risk fraction (PAF) for the key
identified risk factors in themultivariate model (only those
withPAF>5%presented). PAFexpresses theproportionof
events thatwould not have occurredhad that risk factor not
been present and considers both the strengths of the
associations and the incidence rate of the risk factor.
Data from the general population suggest that ESRD and
death are competing outcomes in people with CKD [28].
To test for competing risk between the individual SCE
after CKD we conducted a sensitivity analysis in which
we removed all persons with more than one SCE during
follow-up.
All statistical analyses were carried out using SAS version
9.3 (Cary, North Carolina, USA).
Results
Baseline characteristics
We included 2467 persons with CKD contributing 8636
person-years of follow-up (PYFU) in the analysis. Of
these 2231 (90.4%) had CKD defined by confirmed
eGFR 60ml/min per 1.73m2 or less and 236 persons
(9.6%) by 25% eGFR decline. Persons with CKD were
predominantly white (50.6%) males (77.2%) with a
median age of 60 years (interquartile range, IQR 52–67
years; Table 1). Current smoking was reported in 33.6%,
whereas 16.1% had diabetes, 20.6% hypertension, 59.2%
dyslipidaemia and 10.1% a low BMI (<18 kg/m2). An
eGFR of 30ml/min per 1.73m2 or less was prevalent in
6.3%whereas 49.3 and 26.9% had good (CD4þ cell count
>500 cells/ml and VL<400 copies/ml) and poor (CD4þ
cell count <350 cells/ml or VL >10000 copies/ml) HIV-
status, respectively. As many as 47.9% had experienced
any prior SCE, most commonly an (non-malignant)
AIDS event.
Rates of serious clinical events
During a median follow-up time of 2.7 years (IQR 1.1–
5.1 years), 595 (24.1%) of the 2467 persons with CKD
experienced 826 SCE (incidence rate, IR, 68.9/1000
PYFU [95% confidence interval (CI) 63.4–74.4],
supplementary Figure 1, http://links.lww.com/QAD/
B521. The most common individual SCE was death [IR
32.2/1000 PYFU (28.6–35.8)], followed by NADM [IR
15.2/1000 PYFU (12.7–17.7)], CVD [IR 14.6/1000
PYFU (12.1–17.0)] and other AIDS events [IR 13.0/
1000 PYFU (10.7–15.3)]. There were relatively few
incident ESRD, ESLD and ADM events after CKD with
the follow-up time available.
At one year after CKD, 8.3% (6.9–9.0) were estimated to
have developed any SCE, increasing to 29.3% (26.9–
31.4) at 5 years (Fig. 1). The 1-year and 5-year death rates
were estimated at 4.0% (3.2–4.7%) and 15.3% (13.5–
17.1%), respectively. Of the 313 deaths after CKD, the
most common underlying cause was NADM (23.0%) and
CVD (20.1%). Death with renal failure as the underlying
cause accounted for less than 5%, Supplementary Figure
2, http://links.lww.com/QAD/B521.
Modifiable risk factors
In the following, we focus on the risk factor profiles for
the four most commonly occurring SCEs after CKD;
CVD, NADM, other AIDS events and death. There was
inadequate power to conduct robust adjusted analyses for
ESRD, ESLD and ADM after a CKD diagnosis. In four
separate models, also adjusted for prior SCE, we found
current smoking to be an independent risk factor for all
SCE considered (Fig. 2). In addition to smoking, the risk
profiles differed amongst the individual SCE. Diabetes
was strongly associated with an increased incidence of
CVD, NADM and death, whereas dyslipidaemia was only
significantly associated with CVD. Poor HIV-status
(CD4þ cell count <350 cells/ml or VL >10000 copies/
ml) was significantly associated with other AIDS events
and death. Having an eGFR 30ml/min per 1.73m2 or
less predicted higher rates of CVD and death. Finally, a
low BMI (<18 kg/m2) was significantly associated with
CKD disease burden in HIV-positive persons Ryom et al. 2175
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Table 1. Baseline characteristics.
All CKD No SCE Any SCE
N % N % N % P
Total 2467 100.0 1872 75.9 595 24.1
Sex Male 1904 77.2 1436 76.7 468 78.7 0.32
Race White 1249 50.6 949 50.7 300 50.4 0.88
HIV risk MSM 1171 47.5 908 48.5 263 44.2 0.0031
Injecting drug use 318 12.9 222 11.9 96 16.1
HIV status Poora 663 26.9 397 21.2 266 44.7 <0.0001
ART-naive Yes 19 4.0 14 0.7 5 0.8 0.82
HBV status Positiveb 98 4.0 70 3.7 28 4.7 0.36
HCV status Positivec 555 22.5 393 21.0 162 27.2 0.002
Any prior SCE Yes 1181 47.9 844 45.1 337 56.6 <0.0001
smoking Current 828 33.6 596 31.8 232 39.0 0.0043
Hypertension Yes (mmHg)d 509 20.6 350 18.7 159 26.7 <0.0001
Diabetes Yese 398 16.1 258 13.8 140 23.5 <0.0001
eGFR 30 ml/min per 1.73m2 155 6.3 67 3.6 88 14.8 <0.0001
Dyslipidaemia Yesf 1461 59.2 1055 56.4 406 68.2 <0.0001
BMI <18kg/m2 249 10.1 169 9.0 80 13.4 0.0009
Median IQR Median IQR Median IQR
Age Years 60 52–67 60 52–67 60 51–68 0.92
CD4þ cells/ml 516 345–723 547 380–750 388 250–610 <0.0001
ART, antiretroviral therapy; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; IQR, Interquartile range; SCE, serious clinical
events.
aCD4þ cell count <350cells/ml or VL >10000copies/mL.
bDetection of hepatitis B virus (HBV) surface antigen, HBV e antigen, or HBV-DNA.
cDetection of anti-hepatitis C virus (HCV) and either detection or unknown status of HCV-RNA.
dBlood pressure >150/>100mmHg or receipt of antihypertensive.
eRecording of a diagnosis of diabetes on a D:A:D study event form or receipt of antidiabetics.
fTotal cholesterol level greater than 6.2mmol/l, high-density lipoprotein cholesterol level>0.9mmol/l, triglyceride level>2.3mmol/l, or receipt of
lipid-level-lowering treatment.
Fig. 1. Kaplan–Meier estimationof cumulative incidence of serious clinical events in the 5 years after chronic kidney disease. Each
individual type of SCE was treated as a separate analysis of time to SCE. CKD, chronic kidney disease; SCE, serious clinical events.
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higher rates of other AIDS and death. We did not find
evidence of an interaction between poor HIV-status,
current smoking, low BMI and diabetes for CVD,
NADM, other AIDS events or death (all P> 0.1).
Neither hypertension nor high BMI reached statistical
significance for any of the CKD-related SCE.
The corresponding PAFs for key factors associated with
each of the SCE were calculated (Fig. 3). Had people not
been current smokers between 6.1 and 11% of the
individual SCEs after CKD may not have occurred.
Likewise, a diagnosis of diabetes contributed between 6.4
and 11.5% of all CVD and death events after CKD. A
striking 34.9% of deaths and 13.5% of other AIDS events
in persons with CKD may have been avoided with
optimal HIV-status. An eGFR less than 30ml/min per
1.73m2 or less attributed to 7–13% of all deaths, and
finally, between 9.9 and 19.3% of deaths and CVD could
potentially have been avoided by reducing dyslipidaemia.
Subanalyses
Our findings were consistent after removal of those with
competing events (data not shown), suggesting in this
population of PLWH with more moderate levels of
CKD and with the relatively short median follow-up,
competing risks did not play a major role.
To address the possibility of surveillance bias after CKD,
we tested if the median number of eGFR and CD4þ cell
count measurements differed in the observation period
before and after CKD. If anything there were slightly
fewer eGFR measurements and CD4þ cell counts after
CKD (median 2.6 eGFR/year (2.0–3.3) before and 2.4
eGFR/year (1.6–3.0) after CKD and median 2.2 CD4þ
cell counts/year (1.8–3.0) before and 2.1 CD4þ cell
counts/year (1.4–3.1) after CKD).
Rates of serious clinical events according to
chronic kidney disease status
Having established that people living with both HIVand
CKD have a high burden of SCE and which individual
factors contribute to each of these, we wished to put these
observations into a broader perspective by comparing
rates of SCE in PLWH with and without CKD. In this
descriptive analysis, we included 34 116 persons contrib-
uting 272 424 PYFU without CKD and 2460 persons
contributing 7328 PYFU with CKD. During a median
follow-up of 8.8 (IQR 5.8–10.8) years for those without
CKD 18.5% (n¼ 6300) experienced any SCE [IR 23.0/
1000 PYFU (22.4–23.6)]. In comparison, those with
CKD were followed for a median of 2.1 (IQR 0.4–4.9)
years, during which 18.9% had any incident SCE [IR
63.7/1000 PYFU (57.9–69.5)]. When comparing the
crude IR ratios for individual SCE types amongst PLWH
with and without CKD, except for ADM, the SCE IR
ratios were considerably higher in those with CKD [all
SCE 2.7 (2.5–3.4)], but strongest for ESRD [65.9 (43.8–
100.9)] and death [4.8 (4.3–5.4)] (Fig. 4).
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Fig. 2. Adjusted analysis of risk factor profiles of serious clinical events after chronic kidney disease. aIRR; adjusted incidence
rate ratio. Adjusted for age, sex, ethnicity (those with missing ethnicity were handled as an unknown category), HIV risk
acquisition, baseline date, smoking status, diabetes, hypertension, dyslipidaemia, eGFR, BMI, HBV and HCV status, HIV status
(poor CD4þ cell count< 350/VL>10000; good CD4þ cell count >500/VL< 400; intermediate all other combinations), CD4þ
cell count, previous events (pre-baseline) and time-updated ESLD, ESRD, NADM, ADMother AIDS and CVD (where they were not
the endpoint under consideration). ADM, AIDS-defining malignancies; CKD, chronic kidney disease; eGFR, estimated glomerular
filtration rate; ESLD, end-stage liver disease; ESRD, end-stage renal disease; HBV, hepatitis B virus; HCV, hepatitis C virus; NADM,
non-AIDS-defining malignancies; SCE, serious clinical events.
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Discussion
In this analysis of a large heterogenous cohort we found
that individuals living with both HIVand moderate CKD
have a high burden of SCE, with almost one in three
experiencing a SCE within 5 years of their CKD
diagnosis. The most common SCE was death with a
5-year CKD-related mortality rate exceeding 15%. The
rates of SCE were further almost three times higher in
those with CKD vs. without CKD. Several potentially
2178 AIDS 2019, Vol 33 No 14
Fig. 3. Population attributable fraction of risk factors for individual serious clinical events after chronic kidney disease. The
population attributable fraction (PAF, only shown for those>5%) for each of the individual key risk factors associated with each of
the individual SCE. SCE, serious clinical events.
Fig. 4. Crude serious clinical event incidence rate ratios in people living with HIV with and without chronic kidney disease.
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modifiable risk factors strongly predicted post-CKD
SCE. Our findings suggest more intensified monitoring
and interventions targeted towards these modifiable risk
factors in those with CKD is warranted.
Role of modifiable risk factors in the prognosis
following chronic kidney disease
The rates of prior SCE were high in those with CKD
with over half having experienced an event at baseline,
most commonly an (non-malignant) AIDS event,
suggesting a possible contribution to the development
of CKD. Our data also suggest the SCE rates are already
increased relatively shortly after the CKD diagnosis.
These findings raise the question about the underlying
mechanistics driving SCE after CKD. With this study,
many of the modifiable risk factors previously shown to
predict CKD incidence in PLWH, such as diabetes and
HIV status are now shown to also play an important role
for driving CKD-related morbidity [7,9]. Each CKD-
related SCE had a distinct risk factor profile, as also shown
for CVD, ESRD and mortality among HIV-indetermi-
nant persons with CKD stage G4 in the CRIC study [18].
For NADM after CKD, smoking and diabetes were the
main modifiable predictors, both of which also predicted
CVD together with dyslipidaemia and eGFR less than
30ml/min per 1.73m2. For fatal cases (where NADM
and CVD accounted for 43% of the underlying causes), all
modifiable factors included, apart from dyslipidaemia,
were independently associated with higher incidence
rates, likely reflecting the more heterogenous pathways
leading to death. As many of 35% of all deaths and 14% of
other AIDS events after CKD were directly attributed to
having a poor HIV-status. The higher rates of prior other
AIDS events in those with CKD and the strong
association with poor HIV-status underlines the impor-
tance of avoiding late presentation of HIV, ensuring fast
initiation of effective ARTand high levels for compliance
to ensure a better renal prognosis [29,30]. The percentage
of CVD events and death attributable to diabetes was 6
and 11%, respectively. In the general population, Hallan
et al. also found an essential role of diabetes in CKD
prognosis, and concluded that while CKD stage G3
prevalence is similar in Norway and the United States,
rates of progression to ESRD are 2.5 times higher in the
United States, and closely related to the higher
proportion of diabetics [20]. With a continued increasing
diabetes prevalence in ageing PLWH, this trend may lead
to major adverse health outcomes over time [31].
Smoking was the only modifiable risk factor uniformly
related with increased incidence of all SCE, and a
potential to have prevented up to 11% of deaths had the
person not been a current smoker. A recent large meta-
analysis in the general population also found that among
individuals with CKD stage G4þ diabetes and low eGFR
predicted both CVD and mortality, while smoking only
predicted mortality [32]. The high proportion of smoking
PLWH and the complex interplay between HIV and
smoking in inducing inflammation and immune
exhaustion may, however, possibly explain the wider
SCE association in PLWH than in the general population
[33]. If we succeed in intervening effectively against these
modifiable risks, both the CKD incidence and the CKD-
related prognosis in PLWH are likely to be improved.
Such targeted interventions for CVD-related modifiable
risk factors including dyslipidaemia, hypertension and
smoking have proven effective in reducing CKD-related
CVD risks in the general population [34].
Chronic kidney disease prognostics and the
serious clinical events spectrum
The high rates of CKD-related SCE observed may also
reflect CKD as a marker of a general health deterioration.
Interestingly, however, the monitoring frequency (esti-
mated by median number of eGFR and CD4þ cell count
measurements) did not increase after a CKD diagnosis in
this population. Therefore, while we are unable to fully
exclude the possibility of reverse causality for some of the
SCE after CKD (i.e. ESLD), it seems there is an additional
added impact of the CKD diagnosis itself, which is also
supported by the fact that SCE rates remained high even
after accounting for those who had experienced a prior
SCE. The high SCE rates in those with vs. without CKD
also suggest that CKD itself may induce a worse
prognosis, perhaps by activating additional pathogenic
pathways and reflecting the inability of the kidneys to
remove waste products and maintain electrolyte and
hormonal balance, the increased levels of inflammation
and the compromised immune function [35]. The
underlying cause of CKD stage G3þ is unknown, and
believed to be multifactorial, in up to 20% of all cases in
the general German population [21]. For PLWH, where
there are evenmore potential CKD risk factors and awide
spectrum of renal manifestations, it is indeed possible that
CKD-related SCE are also driven by activating several
different pathways concomitantly [36]. As such, the
combination of HIV status, ongoing risk factors, such as
smoking, and CKD may induce a state of ‘triple trouble’
for increased inflammation, coagulation activation,
oxidative stress, accelerated atherosclerosis and ultimately
increased risks of a broad spectrum of adverse health
outcomes [21,35,37,38].
Although several studies have investigated predictors for
and progression to ESRD, CVD or mortality, few have
investigated the natural history of CKD-associated
morbidity burden in PLWH more broadly [11,14,39–
42]. A 2014 study from EuroSIDA found an association
between current eGFR level, proportion of follow-up
time spent with an eGFR of 60ml/min per 1.73m2 or
less and both AIDS and non-AIDS events, but lacked the
power to look in more detail at individual SCE and the
CKD diagnosis more formally [39]. The study did,
however, also show that time-lagging outcomes did not
change the observations, suggesting the associations are
not simply explained by reverse causality. A Kenyan study
also associated moderately impaired renal function with
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faster progression to AIDS, but did not find an association
with mortality [42], possibly because of both a relatively
short follow-up, limited study size and using a single
measurement of renal impairment likely reflecting a
different underlying mechanism. In the Canadian general
population rates of CVD, mortality and ESRD all
increased with CKD stage, although at considerably lower
rates than those found in our analysis amongst PLWH
[19]. US national sample data from Choi et al. [15] also
suggest that HIV status plays an individual role for the
CKD-related disease burden in that PLWH with CKD
stage G3þ had significantly higher mortality rates
compared with HIV-negative individuals with CKD.
For cancers, data on the association between CKD and
malignancies in PLWH is limited, albeit well described in
the general population. The relation is considered
multifactorial with close relation to shared underlying
risk factors for CKD and malignancies, accumulation of
toxins, oxidative stress and infections as discussed above
[37,39,43]. Progression from CKD stage G3þ to ESRD
is often a gradual process and reflected in the relatively
low number of ESRD events (n¼ 72) in our analysis with
less than 3 years median follow-up time after CKD.
Earlier studies further suggest that age modifies the most
likely CKD-related outcomes in a way where older
individuals are more likely to die rather than develop
ESRD [44]. In this analysis, we did not find strong
evidence of such competing risks but could be because of
the relatively high median age of those with CKD and the
limited follow-up time. The close relation between CKD
stage G3þ and ESRD was, however, evident with a 65
times higher ESRD incidence in those with vs.
without CKD.
Limitations
The most important limitation to acknowledge is the
relatively short follow-up after CKD allowing us only to
conclude about the intermediate-term post-CKD prog-
nosis, although still adequately long to show gradually
increasing rates of all SCE. As the D:A:D study does not
collected proteinuria, we are unable to address any effect
modification hereof and consequently, our SCE rates are
conservative [19]. Due to national regulations data
on ethnicity were missing for a high proportion of
participants (46% without difference between those with
and without SCE, P¼ 0.88), without the possibility to
perform imputations as these data were not missing
randomly. Calculating PAFs based on the effect sizes in
multivariate analysis are intrinsically limited by not taking
into account any potential correlations of these factors
[45]. Finally, we are unable to rule out effects of
unmeasured confounders, such as genetic predispositions
to CKD, use of NSAID and levels of phosphate, calcium,
vitamin D and parathyroid hormone.
Conclusion
In an era where many PLWH require less monitoring
because of effective and well tolerated ART, those living
with even moderate levels of CKD have a high morbidity
andmortality burdenwith almost one in three developing a
SCE within just 5 years. Our data further suggest the
modifiable risk factors smoking, dyslipidaemia, poor HIV-
status, diabetes and low BMI in addition to eGFR less than
30ml/min per 1.73m2 play a central role for CKD-related
morbidity, and highlight the need of increasedmonitoring,
targeted interventions and focus on preventive measures
for those living with both HIV and CKD.
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C. Håkangård (Malm€o).
The ICONA Foundation (Italy):
BOARD OF DIRECTORS
A. d’Arminio Monforte (President), A. Antinori, A.
Castagna, F. Castelli, R. Cauda, G. Di Perri, M. Galli, R.
Iardino, G. Ippolito, G.C. Marchetti, C.F. Perno, F. von
Schloesser, P. Viale.
SCIENTIFIC SECRETARY
A. d’Arminio Monforte, A. Antinori, A. Castagna, F.
Ceccherini-Silberstein, A. Cozzi-Lepri, E. Girardi, S. Lo
Caputo, C. Mussini, M. Puoti.
STEERING COMMITTEE
M. Andreoni, A. Ammassari, A. Antinori, C. Balotta, A.
Bandera, P. Bonfanti, S. Bonora, M. Borderi, A.
Calcagno, L. Calza, M.R. Capobianchi, A. Castagna,
F. Ceccherini-Silberstein, A. Cingolani, P. Cinque, A.
Cozzi-Lepri, A. d’Arminio Monforte, A. De Luca, A. Di
Biagio, E. Girardi, N. Gianotti, A. Gori, G. Guaraldi, G.
Lapadula, M. Lichtner, S. Lo Caputo, G. Madeddu, F.
Maggiolo, G. Marchetti, S. Marcotullio, L. Monno, C.
Mussini, S. Nozza, M. Puoti, E. Quiros Roldan, R.
Rossotti, S. Rusconi, M.M. Santoro, A. Saracino,
M. Zaccarelli.
STATISTICAL AND MONITORING TEAM
A. Cozzi-Lepri, I. Fanti, L. Galli, P. Lorenzini, A.
Rodano, M. Shanyinde, A. Tavelli.
BIOLOGICAL BANK INMI
F. Carletti, S. Carrara, A. Di Caro, S. Graziano, F. Petrone,
G. Prota, S. Quartu, S. Truffa.
PARTICIPATINGPHYSICIANSANDCENTERS
Italy: A. Giacometti, A. Costantini, V. Barocci
(Ancona); G. Angarano, L. Monno, C. Santoro (Bari);
F. Maggiolo, C. Suardi (Bergamo); P. Viale, V. Donati,
G. Verucchi (Bologna); F. Castelli, C. Minardi, E.
Quiros Roldan (Brescia); T. Quirino, C. Abeli (Busto
Arsizio); P.E. Manconi, P. Piano (Cagliari); B. Caco-
pardo, B. Celesia (Catania); J. Vecchiet, K. Falasca
(Chieti); A. Pan, S. Lorenzotti (Cremona); L. Sighinolfi,
D. Segala (Ferrara); F. Mazzotta, F. Vichi (Firenze); G.
Cassola, C. Viscoli, A. Alessandrini, N. Bobbio, G.
Mazzarello (Genova); C. Mastroianni, V. Belvisi
(Latina); P. Bonfanti, I. Caramma (Lecco); A. Chiodera,
P. Milini (Macerata); A. d’Arminio Monforte, M. Galli,
A. Lazzarin, G. Rizzardini, M. Puoti, A. Castagna, G.
Marchetti, M.C. Moioli, R. Piolini, A.L. Ridolfo, S.
Salpietro, C. Tincati (Milano); C. Mussini, C. Puzzo-
lante (Modena); A. Gori, G. Lapadula (Monza); N.
Abrescia, A. Chirianni, G. Borgia, R. Orlando, G.
Bonadies, F. Di Martino, I. Gentile, L. Maddaloni
(Napoli); A.M. Cattelan, S. Marinello (Padova); A.
Cascio, C. Colomba (Palermo); F. Baldelli, E. Schiaroli
(Perugia); G. Parruti, F. Sozio (Pescara); G. Magnani,
M.A. Ursitti (Reggio Emilia); M. Andreoni, A.
Antinori, R. Cauda, A. Cristaudo, V. Vullo,
R. Acinapura, G. Baldin, M. Capozzi, S. Cicalini, A.
Cingolani, L. Fontanelli Sulekova, G. Iaiani, A. Latini,
I. Mastrorosa, M.M. Plazzi, S. Savinelli, A. Vergori
(Roma); M. Cecchetto, F. Viviani (Rovigo); G.
Madeddu, P. Bagella (Sassari); A. De Luca, B. Rossetti
(Siena); A. Franco, R. Fontana Del Vecchio (Siracusa);
D. Francisci, C. Di Giuli (Terni); P. Caramello, G. Di
Perri, S. Bonora, G.C. Orofino, M. Sciandra (Torino);
M. Bassetti, A. Londero (Udine); G. Pellizzer,
V. Manfrin (Vicenza), G. Starnini, A. Ialungo
(Viterbo).
Nice HIV Cohort (France):
Central coordination: C. Pradier, E. Fontas, K. Dollet,
C. Caissotti.
CKD disease burden in HIV-positive persons Ryom et al. 2185
 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Participating physicians: P. Dellamonica, E. Bernard,
J. Courjon, E. Cua, F. De Salvador-Guillouet, J. Durant,
C. Etienne, S. Ferrando, V. Mondain-Miton, A. Naqvi, I.
Perbost, S. Pillet, B. Prouvost-Keller, P. Pugliese, V. Rio,
K. Risso, P.M. Roger.
SHCS (Swiss HIV Cohort Study, Switzerland):
The data are gathered by the Five Swiss University
Hospitals, two Cantonal Hospitals,15 affiliated hospitals
and 36 private physicians (listed in http://www.shcs.ch/
180-health-care-providers).
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Gilead Sciences; Bristol-Myers Squibb; Boehringer
Ingelheim; Janssen-Cilag; ViiV Healthcare. The Kirby
Institute is funded by The Australian Government
Department of Health and Ageing, and is affiliated with
the Faculty of Medicine, The University of New South
Wales; by grants from the Fondo de Investigacion
Sanitaria (grant number FIS 99/0887) and Fundacion
para la Investigacion y la Prevencion del SIDA en
Espanã (grant number FIPSE 3171/00), to the
Barcelona Antiretroviral Surveillance Study (BASS);
by the National Institute of Allergy and Infectious
Diseases, National Institutes of Health (grants number
5U01AI042170-10, 5U01AI046362-03), to the Terry
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